Podcast
Lung Cancer Update
Hosted by Dr. Neil Love · EN
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
33episodes
Episodes
Newest firstAll episodes
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR
1w ago00:59:01Tap to summarizeFeaturing perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics:Introduction: Relative Impact of Targeted Treatment (00:00)HER2 Alterations (8:04)KRAS Mutations (24:25)MET Overexpression (30:34)ALK Fusions (32:34)ROS1 Fusions (42:36)RET Fusions (52:00)CME information and select publications
Transcribe →HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3
2w ago00:30:11Tap to summarizeFeaturing perspectives from Dr Joshua K Sabari, including the following topics:Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37)CME information and select publications
Transcribe →HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2
2w ago00:16:53Tap to summarizeFeaturing perspectives from Dr Joshua K Sabari, including the following topics:Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37)CME information and select publications
Transcribe →EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
3w ago01:57:57Tap to summarizeFeaturing perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00)Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)CME information and select publications
Transcribe →HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
Jul 1400:27:32Tap to summarizeFeaturing an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)CME information and select publications
Transcribe →Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft
Jul 1100:59:55Tap to summarizeFeaturing an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)Importance of clinical trials in the adjuvant setting (33:02)Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)CME information and select publications
Transcribe →For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
Jul 801:28:54Tap to summarizeFeaturing perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:Introduction (0:00)Overview of Antibody-Drug Conjugates (ADCs) (2:07)Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)Currently Available ADCs for Gynecologic Cancer Management (26:37)Currently Available ADCs for Lung Cancer Management (44:07)Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)NCPD information and select publications
Transcribe →Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 3000:50:08Tap to summarizeFeaturing perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00)Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)CME information and select publications
Transcribe →EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 2700:51:09Tap to summarizeFeaturing perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics:Introduction (0:00)Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38)Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20)CME information and select publications
Transcribe →First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
Jun 1800:40:45Tap to summarizeFeaturing an interview with Prof Martin Reck, including the following topics:Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)Considerations with maintenance therapy for ES-SCLC (9:31)Considerations with immunotherapy for ES-SCLC (13:12)Curability of SCLC with systemic therapy (15:17)Data with chemoimmunotherapy for patients with poor performance status (25:55)Future developments in therapy for SCLC (30:11)Rapid fire: Small Cell 101 (35:45)CME information and select publications
Transcribe →